Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B

This study is currently recruiting participants.
Verified April 2014 by Peking University First Hospital
Sponsor:
Collaborator:
Beijing Municipal Science & Technology Commission
Information provided by (Responsible Party):
Guiqiang Wang, Peking University First Hospital
ClinicalTrials.gov Identifier:
NCT01679769
First received: September 1, 2012
Last updated: April 14, 2014
Last verified: April 2014

September 1, 2012
April 14, 2014
May 2012
August 2015   (final data collection date for primary outcome measure)
Quality of staging fibrosis with a combination of non-invasive parameters compared to liver biopsy [ Time Frame: singular evaluation at the time of liver biopsy ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT01679769 on ClinicalTrials.gov Archive Site
quality of staging inflammation with a combination of non-invasive parameters compared to liver biopsy [ Time Frame: singular evaluation at the time of liver biopsy ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B
Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic

The aim of our study is to evaluate liver fibrosis using biochemical markers, FibroScan, and radiology methods in patients with chronic hepatitis B in mainland China.

Not Provided
Observational [Patient Registry]
Time Perspective: Prospective
2 Weeks
Retention:   Samples Without DNA
Description:

liver biopsy samples and blood samples

Non-Probability Sample

patients with chronic hepatitis B or compensated cirrhosis due to chronic hepatits B virus (HBV) infection

Chronic Hepatitis B
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
720
December 2015
August 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • clinical diagnosis of chronic hepatitis B or compensated cirrhosis due to chronic hepatitis B virus infection
  • agree to have liver biopsy

Exclusion Criteria:

  • clinical diagnosis of decompensated cirrhosis due to hepatitis B virus or inactive carrier
  • liver diseases due to other origin
Both
18 Years to 75 Years
No
Contact: hong zhao, MD 13810765943 minmin2001@gmail.com
Contact: Guiqiang Wang, MD 13911405123 john131212@126.com
China
 
NCT01679769
2012-455, 81170386
Yes
Guiqiang Wang, Peking University First Hospital
Peking University First Hospital
Beijing Municipal Science & Technology Commission
Principal Investigator: Guiqiang Wang, MD Peking University First Hospital
Study Director: Hong Zhao, MD Peking University First Hospital
Peking University First Hospital
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP